Investigational new drugs in the treatment of inflammatory bowel disease: a review

References

• BeanRHThe treatment of chronic ulcerative colitis with 6-mercaptopurineMed J Aust196249259259313969929
   PubMed Web of Science ®Google Scholar
• Van DeventerSJTumour necrosis factor and Crohn’s diseaseGut1997404434489176068
   PubMed Web of Science ®Google Scholar
• RutgeertsPVermeireSvan AsscheGBiological therapies for inflammatory bowel diseasesGastroenterology20091361182119719249397
   PubMed Web of Science ®Google Scholar
• GrimmMCNew and emerging therapies for inflammatory bowel diseasesJ Gastroenterol Hepatol200924Suppl 3S69S7419799702
   PubMed Web of Science ®Google Scholar
• AtreyaRNeurathMFNew therapeutic strategies for treatment of inflammatory bowel diseaseMucosal Immunol2008117518219079177
   PubMed Web of Science ®Google Scholar
• RoglerGMichettiPKrugerFActive therapeutic immunization against TNF with a TNF-kinoid in Crohn’s disease patients: a Phase 1–2 studyGastroenterology2010138Suppl 1517
   Google Scholar
• EngelMANeurathMFNew pathophysiological insights and modern treatment of IBDJ Gastroenterol20104557158320213337
   PubMed Web of Science ®Google Scholar
• ItoHTakazoeMFukudaYA pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active crohn’s diseaseGastroenterol20041264989996
   PubMed Web of Science ®Google Scholar
• BeckerCFantiniMCSchrammCTGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signallingImmunity20042149150115485627
   PubMed Web of Science ®Google Scholar
• GrivennikovSKarinETerzicJIL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis associated cancerCancer Cell20091510311319185845
   PubMed Web of Science ®Google Scholar
• LyakhLTrinchieriGProvezzaLRegulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humansImmunol Rev200822611213119161420
   PubMed Web of Science ®Google Scholar
• NeurathMFFussIKelsallBLAntibodies to interleukin 12 abrogate established experimental colitis in miceJ Exp Med1995182128112907595199
   PubMed Web of Science ®Google Scholar
• DavidsonNJHudakSALesleyREIL-12, but not IFN-γ, plays a major role in sustaining the chronic phase of colitis in IL-10 deficient miceJ Immunol1998161314331499743382
   PubMed Web of Science ®Google Scholar
• HueSAhernPBuonocoreSInterleukin-23 drives innate and T cell mediated intestinal inflammationJ Exp Med20062032473248317030949
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBJFedorakRNUstekinumab Crohn’s Disease Study Group. A randomised trial of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with moderate to severe Crohn’s diseaseGastroenterology20081351130114118706417
   PubMed Web of Science ®Google Scholar
• PanaccioneRSandbornWGordonGBriakinumab (ABT874) for treatment of Crohn’s diseaseGut201059Suppl 3A11
   Google Scholar
• WaldnerMJNeurathMFNovel cytokine-targeted therapies and intestinal inflammationCurr opin Pharm20099702707
   PubMed Web of Science ®Google Scholar
• DaneseSAngelucciEMalesciACaprilliRBiological agents for ulcerative colitis: hypes and hopesMed Res Rev200828220121817464967
   PubMed Web of Science ®Google Scholar
• ReinischWHommesDWvan AsscheGA dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn’s diseaseGut2006551138114416492717
   PubMed Web of Science ®Google Scholar
• Van AsscheGDalleINomanMA pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitisAm J Gastroenterol20039836937612591057
   PubMed Web of Science ®Google Scholar
• BraatHRottiersPHommesDWA Phase I trial with transgenic bacteria expressing IL-10 in Crohn’s diseaseClin Gastroenterol Hepatol2006475475916716759
   PubMed Web of Science ®Google Scholar
• TilgHVogelsangHLudwiczekOA randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitisGut2003521728173314633951
   PubMed Web of Science ®Google Scholar
• Pena-RossiCSchreiberSGolubovicGClinical trial: a multicentre, randomised, double blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitisAiliment Pharmacol Ther200828758767
   PubMed Web of Science ®Google Scholar
• SiegmundBTargeted therapies in inflammatory bowel diseaseDig Dis20092746546919897961
   PubMed Web of Science ®Google Scholar
• SolerDChapmanTYangLWyantTEganRFedykERThe binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseasesJ Pharmacol Exp Therap2009330386487519509315
   PubMed Web of Science ®Google Scholar
• HesterbergPEWinsor-HinesDBriskinMJRapid resolution of chronic colitis in the cotton-top tamarin with an antibody to the gut-homing integrin alpha 4 beta 7Gastroenterology1996111137313808898653
   PubMed Web of Science ®Google Scholar
• PicarellaDHurlbutPRottmanJShiXButcherERinglerDJMonoclonal antibodies specific beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cellsJ Immunol1997158209921069036954
   PubMed Web of Science ®Google Scholar
• LobbRRHelmerMEThe pathophysiologic role of alpha 4 integrins in vivoJ Clin Invest1994172217287525645
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMastersBKTylerKLProgressive multifocal leucoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Eng J Med2005353369374
   PubMed Web of Science ®Google Scholar
• Van AsscheGvan RanstMSciotRProgressive multifocal leucoencephalopathy after natalizumab therapy for Crohn’s diseaseN Eng J Med2005353362368
   PubMed Web of Science ®Google Scholar
• ButcherECWilliamsMYoungmanKRottLBriskinMLymphocyte trafficking and regional immunityAdv Immunol19997220925310361577
   PubMed Web of Science ®Google Scholar
• SalmiMJalkanenSLymphocyte homing to the gut; attraction, adhesion and commitmentImmunol Rev200520610011316048544
   PubMed Web of Science ®Google Scholar
• FeaganBGGreenbergGRWildGtreatment of ulcerative colitis with a humanised antibody to the alpha4beta7 integrinN Eng J Med200535224992507
   PubMed Web of Science ®Google Scholar
• FeaganBGGreenbergGRWildGTreatment of active Crohn’s disease with MLN0002, a humanised antibody to the alpha4-beta7 integrinClin Gastroenterol Hepatol200861370137718829392
   PubMed Web of Science ®Google Scholar
• EksteenBAdamsDHGSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn’s diseaseIDrugs201013747278120582872
   PubMed Web of Science ®Google Scholar
• StronkhorstARademaSYongSLCD4 antibody treatment in patients with active Crohn’s disease: a phase I dose finding studyGut1997403203279135519
   PubMed Web of Science ®Google Scholar
• MayerLEvolving paradigms in the pathogenesis of IBDJ Gastroenterol20104591619960355
   PubMed Web of Science ®Google Scholar
• Van AsscheGSandbornWJFeaganBGDaclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialGut2006551568157416603634
   PubMed Web of Science ®Google Scholar
• HanauerSSandbornWSandsBEA randomized placebo-controlled trial of Abatacept for moderately-to-severely active Crohn’s diseaseGastroenterology2010138Supp 186
   Google Scholar
• GoetzMAtreyaRGhalibafianMGallePRNeurathMFExacerbation of Ulcerative colitis following Rituximab salvage therapyInflamm Bowel Dis200713111365136817604367
   PubMed Web of Science ®Google Scholar
• SchrezenmeirJde VresesMProbiotics, prebiotics and synbiotics-approaching a definitionAm J Clin Nutr200173361S364S11157342
   PubMed Web of Science ®Google Scholar
• SartorRBTherapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, prebiotics and probioticsGastroenterology20041261620163315168372
   PubMed Web of Science ®Google Scholar
• RoberfroidMPrebiotics: the concept revisitedJ Nutr2007137830S837S17311983
   PubMed Web of Science ®Google Scholar
• KleessenBHartmannLBlautMOligofructose and long chain inulin: influence on the gut microbial ecology of rats associated with a human faecal floraBr J Nutr20018629130011502244
   PubMed Web of Science ®Google Scholar
• SantosASanMMDiazDMPrebiotics and their long term influence on the microbial populations of the mouse bowelFood Microbiol20062349850316943043
   PubMed Web of Science ®Google Scholar
• GibsonGRBeattyERWangXSelective stimulation of bifidobacteria in the human colon by oligofructose and inulinGastroenterology19951089759827698613
   PubMed Web of Science ®Google Scholar
• CampbellJMFaheyGCJrWolfBWSelected indigestible oligosaccharides affect large bowel mass, caecal and faecal short chain fatty acids, pH and microflora in ratsJ Nutr19971271301369040556
   PubMed Web of Science ®Google Scholar
• WongJMde SouzaRKendallCWEmamAJenkinsDJColonic health: fermentation and short chain fatty acidsJ Clin Gastroenterol20064023524316633129
   PubMed Web of Science ®Google Scholar
• GionchettiPRizzelloFHelwigUProphylaxis of pouchitis onset with probiotic therapy: a double blind, placebo controlled trialGastroenterology20031241202120912730861
   PubMed Web of Science ®Google Scholar
• MimuraTRizzelloFHelwigUOnce daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitisGut20045310811414684584
   PubMed Web of Science ®Google Scholar
• QuigleyEMMPrebiotics and probiotics; modifying and mining the microbiotaPharm Res201061213218
   Web of Science ®Google Scholar
• AndersonREOlaisonGTyskCAppendectomy and protection against ulcerative colitisN Eng J Med2001344808814
   Web of Science ®Google Scholar
• DerbyLEJickHAppendectomy protects against ulcerative colitisEpidemiology199892052079504292
   PubMed Web of Science ®Google Scholar
• CalkinsBMA meta-analysis of the role of smoking in inflammatory bowel diseaseDig Dis Sci198934184118542598752
   PubMed Web of Science ®Google Scholar
• SonnenbergAMcCartyDJJacobsenSJGeographic variation of inflammatory bowel disease within the united statesGastroenterology19911001431491983816
   PubMed Web of Science ®Google Scholar
• ShivanandaSLennard-JonesJLoganRIncidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative study on inflammatory bowel disease (EC-IBD)Gut1996396906979014768
   PubMed Web of Science ®Google Scholar
• WeinstockJVElliottDEHelminths and the IBD hygiene hypothesisInflamm Bowel Dis20091512813318680198
   PubMed Web of Science ®Google Scholar
• KhanWIBlennerhassetPAVargheseAKIntestinal nematode infection ameliorates experimental colitis in miceInfect Immun2002705931593712379667
   PubMed Web of Science ®Google Scholar
• MoreelsTGNieuwendijkRJde ManJGConcurrent infection with schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in ratsGut2004539910714684583
   PubMed Web of Science ®Google Scholar
• SummersRWElliotDEUrbanJFJrTrichuris suis therapy in Crohn’s diseaseGut200554879015591509
   PubMed Web of Science ®Google Scholar
• SummersRWElliotDEUrbanJFJrTrichuris suis therapy for active ulcerative colitis: a randomised controlled trialGastroenterology200512882583215825065
   PubMed Web of Science ®Google Scholar
• MitsuyamaKSataMTherapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of actionEx Cytotherapy2009112229237
   PubMed Web of Science ®Google Scholar
• ArseneauKOCominelliFLeukocytapheresis in ulcerative colitis: a possible alternative to biological therapy?Dig Liver Dis20094155155219540820
   PubMedGoogle Scholar
• SandsBESandbornWJFeaganBA randomized, double-blind, sham controlled study of granulocyte/monocyte apheresis for active ulcerative colitisGastroenterology200813540040918602921
   PubMed Web of Science ®Google Scholar
• GodoiDFCardosoCRFerrazDBHemopoietic SCT modulates gut inflammation in experimental inflammatory bowel diseaseBone Marrow Trans2010110
   Web of Science ®Google Scholar
• OyamaYCraigRMTraynorAEAutologous hematopoietic stem cell transplantation in patients with refractory Crohn’s diseaseGastroenterology2005128355256315765390
   PubMed Web of Science ®Google Scholar
• PranteraCLochsHGionchettiPRifaximin-EIR 400 mg tablets in the treatment of moderately active Crohn’s disease: results of the International, multicentre, randomized, double-blind, placebo-controlled trial RETIC-03Gut201059Suppl 3A1
   Google Scholar